Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points

Amgen (NASDAQ: AMGN) and AstraZeneca announced positive results from the Phase 3 CROSSING trial for TEZSPIRE (tezepelumab-ekko), showing histologic remission in 64.8% of patients at the 210 mg dose and 68.9% at the 420 mg dose at week 24, compared to 3.5% for placebo (p<0.001). Additionally, TEZSPIRE reduced dysphagia symptoms by 18.8 points for the 210 mg dose and 22.0 points for the 420 mg dose, significantly outperforming the placebo group. These improvements were sustained through week 52 for patients with symptomatic and uncontrolled eosinophilic esophagitis.